Open

Chronic Myelogenous Leukemia Study

The purpose of the study is to see how safe and how well the study drug (asciminib) works for patients with CML-CP who have had one prior therapy.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At each visit, you will be required to receive study treatment, physical examination of vital signs, blood sample collection and mutation testing, pregnancy testing, regular ECG scans, and questionnaires to complete.

In-person visits:
30

Total length of participation:
2 years

Looking for Specific Volunteers

Able to participate:

You have Chronic Myelogenous Leukemia
You are not pregnant or breastfeeding

Not eligible if:

You are participating in another treatment study
You are pregnant or breastfeeding

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Joshua Zeidner
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

23-0500

ClinicalTrials.gov

NCT05384587

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.